Literature DB >> 9739379

Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome.

P Huguenin1, C Glanzmann, D Taussky, U M Lütolf, S Schmid, K Moe.   

Abstract

PURPOSE: To assess the survival rate, the probability of local control, the patterns of relapse and late sequelae including self-reported quality of life in patients treated with hyperfractionated radiotherapy (RT) and simultaneous CDDP chemotherapy for stage-III to stage-IV carcinomas of the head and neck.
METHODS: From 1988 to 1994, 64 patients (median age 55.5 years) with carcinomas of different subsites, excluding the nasopharynx, were treated in a pilot study with 1.2 Gy bid (6 h interval; total dose 74.4 Gy) and simultaneous CDDP (20 mg/m2 daily, 5 days in week 1 and 5) and followed at regular intervals. Overall survival and local control, as well as the rates of late toxicity, were estimated using the actuarial method. Median follow-up was 3.3 years for all and 5.2 years for surviving patients. To assess the quality of life, the EORTC QLQ-C 30 questionnaire and the H&N35 module questionnaire were sent to the patients surviving with no evidence of disease or second primary tumors; they were answered by 15/23 (67%).
RESULTS: Overall survival was 37% at 5 years, whereas disease-specific survival was 59%. Twenty-three patients died from uncontrolled head and neck cancer. Second primary tumors were observed in 13 patients, most frequently in the lung. Local control without salvage surgery was 74% at 5 years for all subsites and stages, and loco-regional disease-free survival was 72%. Eleven patients developed distant metastases, which was the only site of failure in 6 cases. Salvage surgery was successful in 2 cases. The actuarial estimates of > or = grade-3 late toxicity was 4% for the mandibular bone and 23% for dysphagia, and 50% of the patients experienced a permanent xerostomy. Self-reported global quality of life in surviving patients was good (mean 68 points on a scale 0 to 100); consequences of impaired salivary function had most impact on nutritional and social aspects.
CONCLUSIONS: Hyperfractionated RT with concomitant CDDP is well tolerated and highly efficient in controlling moderately advanced to advanced cancers of the head and neck. Second primary tumors are the main cause of death after 3 years and were observed outside of the irradiated area, most frequently in the lung. Even after RT of large volumes to a high dose, salvage surgery can be successfully performed in individual cases. Self-reported quality of life of surviving patients is good, despite xerostomy-associated nutritional difficulties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739379     DOI: 10.1007/bf03038560

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  20 in total

1.  Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer.

Authors:  L B Harrison; D G Pfister; D E Fass; J G Armstrong; R B Sessions; J P Shah; R H Spiro; E W Strong; S Weisen; G J Bosl
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-08       Impact factor: 7.038

Review 2.  Radiotherapy with concomitant chemotherapy for head and neck cancer.

Authors:  E E Vokes; A M Awan; R R Weichselbaum
Journal:  Hematol Oncol Clin North Am       Date:  1991-08       Impact factor: 3.722

3.  Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17.

Authors:  V A Marcial; T F Pajak; M Mohiuddin; J S Cooper; M al Sarraf; P A Mowry; W Curran; J Crissman; M Rodríguez; E Vélez-García
Journal:  Cancer       Date:  1990-11-01       Impact factor: 6.860

4.  Radiotherapy plus chemotherapy for head and neck cancer.

Authors:  W M Mendenhall; J T Parsons
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

Review 5.  Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience.

Authors:  J S Cooper; T F Pajak; P Rubin; L Tupchong; L W Brady; S A Leibel; G E Laramore; V A Marcial; L W Davis; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-09       Impact factor: 7.038

6.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.

Authors:  M Merlano; V Vitale; R Rosso; M Benasso; R Corvò; M Cavallari; G Sanguineti; A Bacigalupo; F Badellino; G Margarino
Journal:  N Engl J Med       Date:  1992-10-15       Impact factor: 91.245

9.  Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group.

Authors:  K Bjordal; M Ahlner-Elmqvist; E Tollesson; A B Jensen; D Razavi; E J Maher; S Kaasa
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

10.  Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.

Authors:  M Merlano; M Benasso; R Corvò; R Rosso; V Vitale; F Blengio; G Numico; G Margarino; L Bonelli; L Santi
Journal:  J Natl Cancer Inst       Date:  1996-05-01       Impact factor: 13.506

View more
  5 in total

Review 1.  Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies.

Authors:  Douglas E Peterson; Wolfgang Doerr; Allan Hovan; Andres Pinto; Debbie Saunders; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-06-06       Impact factor: 3.603

2.  Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.

Authors:  Katherine Y Fan; Hrishikesh Gogineni; David Zaboli; Spencer Lake; Marianna L Zahurak; Simon R Best; Marshall A Levine; Mei Tang; Eva S Zinreich; John R Saunders; Joseph A Califano; Ray G Blanco; Sara I Pai; Barbara Messing; Patrick K Ha
Journal:  Ann Surg Oncol       Date:  2012-06       Impact factor: 5.344

Review 3.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

4.  Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Authors:  Matthias G Hautmann; Matthias Hipp; Oliver Kölbl
Journal:  Radiat Oncol       Date:  2011-08-01       Impact factor: 3.481

5.  PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison.

Authors:  Sacha Rothschild; Gabriela Studer; Burkhardt Seifert; Pia Huguenin; Christoph Glanzmann; J Bernard Davis; Urs M Lütolf; Thomas F Hany; I Frank Ciernik
Journal:  Radiat Oncol       Date:  2007-06-09       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.